OSE-2101の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

OSE-2101（Tedopi）は、OSE Immunotherapeuticの最先端製品であり、治療用ネオエピトープ系ワクチンで、T細胞を特異的に活性化する5つの腫瘍抗原から選択され最適化された9つのネオエピトープと、T細胞の活性化を標的とした万能ヘルパーT細胞応答を与える1つのエピトープを独自に組み合わせたものです。Tedopiは、細胞傷害性応答の重要な受容体であるHLA-A2+患者向けに設計された治療薬です。

現在、Tedopiは3群からなるTEDOVAフェーズII試験で検討されており、腫瘍学協同グループARCAGY-GINECOの支援のもと、プラチナ製剤感受性再発卵巣がん患者を対象に、プラチナ製剤ベースの化学療法後に病勢がコントロールされた場合の維持療法として、単独または抗PD-1薬キイトルーダとの併用で、最良の支持療法と比較評価されています。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における卵巣がん向けOSE-2101について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 卵巣がんにおけるOSE-2101の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 OSE-2101市場の評価

• 卵巣がんにおけるOSE-2101の市場見通し
• 主要7市場の分析
  • 主要7市場の卵巣がん向けOSE-2101の市場規模
• 市場の分析：国別
  • 米国の卵巣がん向けOSE-2101の市場規模
  • ドイツの卵巣がん向けOSE-2101の市場規模
  • 英国の卵巣がん向けOSE-2101の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: OSE-2101, Clinical Trial Description, 2023
• Table 2: OSE-2101, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: OSE-2101 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: OSE-2101 Market Size in the US, in USD million (2019-2032)
• Table 7: OSE-2101 Market Size in Germany, in USD million (2019-2032)
• Table 8: OSE-2101 Market Size in France, in USD million (2019-2032)
• Table 9: OSE-2101 Market Size in Italy, in USD million (2019-2032)
• Table 10: OSE-2101 Market Size in Spain, in USD million (2019-2032)
• Table 11: OSE-2101 Market Size in the UK, in USD million (2019-2032)
• Table 12: OSE-2101 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: OSE-2101 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: OSE-2101 Market Size in the United States, USD million (2019-2032)
• Figure 3: OSE-2101 Market Size in Germany, USD million (2019-2032)
• Figure 4: OSE-2101 Market Size in France, USD million (2019-2032)
• Figure 5: OSE-2101 Market Size in Italy, USD million (2019-2032)
• Figure 6: OSE-2101 Market Size in Spain, USD million (2019-2032)
• Figure 7: OSE-2101 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: OSE-2101 Market Size in Japan, USD million (2019-2032)

"OSE-2101 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OSE-2101 for ovarian cancer in the seven major markets. A detailed picture of the OSE-2101 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OSE-2101 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OSE-2101 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

OSE-2101 (Tedopi) - OSE Immunotherapeutic's most advanced product and therapeutic neo-epitope-based vaccine - is a proprietary combination of nine optimized neo-epitopes, selected and optimized from five tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell activation. It is a treatment designed for HLA-A2+ patients, a key receptor of the cytotoxic response.

Currently, Tedopi is being studied in a three-arm TEDOVA Phase II study, which is evaluating it as a maintenance treatment, alone or in combination with the anti-PD-1 KEYTRUDA, versus the best supportive care in platinum-sensitive recurrent ovarian cancer patients, with the controlled disease after platinum-based chemotherapy under the sponsorship of cooperative group in oncology ARCAGY-GINECO.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the OSE-2101 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on OSE-2101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OSE-2101 research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around OSE-2101.
• The report contains forecasted sales of OSE-2101 for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for OSE-2101 in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OSE-2101 Analytical Perspective by DelveInsight

• In-depth OSE-2101 Market Assessment

This report provides a detailed market assessment of OSE-2101 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• OSE-2101 Clinical Assessment

The report provides the clinical trials information of OSE-2101 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OSE-2101 dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to OSE-2101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OSE-2101 in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of OSE-2101 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OSE-2101 in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of OSE-2101?
• What is the clinical trial status of the study related to OSE-2101 in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OSE-2101 development?
• What are the key designations that have been granted to OSE-2101 for ovarian cancer?
• What is the forecasted market scenario of OSE-2101 for ovarian cancer?
• What are the forecasted sales of OSE-2101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to OSE-2101 for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. OSE-2101 Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. OSE-2101 Market Assessment

• 5.1. Market Outlook of OSE-2101 in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of OSE-2101 in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of OSE-2101 in the United States for ovarian cancer
  • 5.3.2. Market Size of OSE-2101 in Germany for ovarian cancer
  • 5.3.3. Market Size of OSE-2101 in France for ovarian cancer
  • 5.3.4. Market Size of OSE-2101 in Italy for ovarian cancer
  • 5.3.5. Market Size of OSE-2101 in Spain for ovarian cancer
  • 5.3.6. Market Size of OSE-2101 in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of OSE-2101 in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options